Kavanaugh Arthur
Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093-0943, USA.
Curr Opin Rheumatol. 2007 May;19(3):272-6. doi: 10.1097/BOR.0b013e3280be58ee.
Pharmacoeconomic evaluations are increasingly important in all aspects of medicine. In rheumatology, such studies have become all the more relevant following the introduction of highly effective biologic agents. Brought to the clinic initially for the treatment of rheumatoid arthritis, biologic agents have found expanded indication in other rheumatic diseases.
Building upon a long tradition in rheumatology, recent studies have updated and expanded upon the costs of various rheumatic diseases. These studies set the stage for determining the value of newer therapies. As a result of the chronic nature of rheumatic diseases, pharmacoeconomic evaluations must be carried out over sufficiently long time frames. Therefore, methodologic issues continue to be an area of ongoing discussion. Finally, ongoing studies have estimated the cost-effectiveness of novel rheumatologic therapies, in particular the inhibitors of tumor necrosis factor. These studies have shown that in several clinical circumstances, tumor necrosis factor inhibitors can indeed have an incremental cost-efficacy within the range of generally accepted medical interventions. While many of these studies focused on rheumatoid arthritis, there is growing interest in pharmacoeconomic evaluations in other rheumatic diseases.
Pharmacoeconomic evaluations are crucial to the optimal use of new therapies in rheumatology.
药物经济学评估在医学的各个方面日益重要。在风湿病学领域，随着高效生物制剂的引入，此类研究变得愈发重要。生物制剂最初应用于临床是为了治疗类风湿关节炎，如今已在其他风湿性疾病中发现了更广泛的适应症。
基于风湿病学的悠久传统，近期研究更新并拓展了各种风湿性疾病的成本。这些研究为确定新疗法的价值奠定了基础。由于风湿性疾病的慢性特点，药物经济学评估必须在足够长的时间范围内进行。因此，方法学问题仍是一个持续讨论的领域。最后，正在进行的研究评估了新型风湿病疗法的成本效益，特别是肿瘤坏死因子抑制剂。这些研究表明，在几种临床情况下，肿瘤坏死因子抑制剂在一般公认的医学干预范围内确实具有增量成本效益。虽然这些研究大多聚焦于类风湿关节炎，但对其他风湿性疾病的药物经济学评估的兴趣也在不断增加。
药物经济学评估对于在风湿病学中优化使用新疗法至关重要。
Zotero 插件